9.32
0.00 (0.00%)
| Previous Close | 9.32 |
| Open | 9.28 |
| Volume | 17,591 |
| Avg. Volume (3M) | 95,337 |
| Market Cap | 94,387,368 |
| Price / Sales | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | -27.54% |
| Operating Margin (TTM) | 1.58% |
| Diluted EPS (TTM) | -2.12 |
| Quarterly Revenue Growth (YOY) | 12.90% |
| Current Ratio (MRQ) | 0.770 |
| Operating Cash Flow (TTM) | -44.68 M |
| Levered Free Cash Flow (TTM) | -34.05 M |
| Return on Assets (TTM) | -8.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | OptiNose, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -1.25 |
|
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 6.42% |
| % Held by Institutions | 73.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mvm Partners, Llc | 31 Dec 2024 | 973,684 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (Piper Sandler, -3.43%) | Hold |
| 9.00 (HC Wainwright & Co., -3.43%) | Hold | |
| 9.00 (Lake Street, -3.43%) | Hold | |
| Median | 9.00 (-3.43%) | |
| Average | 9.00 (-3.43%) | |
| Total | 3 Hold | |
| Avg. Price @ Call | 9.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Mar 2025 | 9.00 (-3.43%) | Hold | 9.15 |
| Piper Sandler | 21 Mar 2025 | 9.00 (-3.43%) | Hold | 9.15 |
| Lake Street | 20 Mar 2025 | 9.00 (-3.43%) | Hold | 9.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Mar 2025 | Announcement | Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights |
| 20 Mar 2025 | Announcement | OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals |
| 19 Mar 2025 | Announcement | Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call |
| 11 Mar 2025 | Announcement | Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |